ProVision is a Eureka Eurostars project to deliver a cutting edge, organ-specific PET scanner capable of detecting small aggressive prostate tumours at an early stage, when the disease is still curable.

ProVision brings together a state-of-the-art PET scanner, an imaging software driven by Artificial Intelligence and the next generation of radiotracers. This will allow a diagnostic system to be built and be employed immediately after an abnormal PSA blood test.

ProVision is a European collaborative project, with partners of Picotech (FR), Trasis (BE) and the Unversity Hospital of Geneva (CH), this project was classified third out of 369 eligible submissions.

ProVision will be an innovation with a significant social impact that makes the screening of prostate cancer a reality.